|
1.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2.
|
Daigo Y, Takano A, Teramoto K, Chung S and
Nakamura Y: A systematic approach to the development of novel
therapeutics for lung cancer using genomic analyses. Clin Pharmacol
Ther. 94:218–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Inoue A, Saijo Y, Maemondo M, et al:
Severe acute interstitial pneumonia and gefitinib. Lancet.
361:137–139. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Sandomenico C, Costanzo R, Carillio G, et
al: Bevacizumab in non small cell lung cancer: development, current
status and issues. Curr Med Chem. 19:961–971. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Daigo Y and Nakamura Y: From cancer
genomics to thoracic oncology: discovery of new biomarkers and
therapeutic targets for lung and esophageal carcinoma. Gen Thorac
Cardiovasc Surg. 56:43–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Kikuchi T, Daigo Y, Katagiri T, et al:
Expression profiles of non-small cell lung cancers on cDNA
microarrays: identification of genes for prediction of lymph-node
metastasis and sensitivity to anti-cancer drugs. Oncogene.
22:2192–2205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Kakiuchi S, Daigo Y, Tsunoda T, Yano S,
Sone S and Nakamura Y: Genome-wide analysis of organ-preferential
metastasis of human small cell lung cancer in mice. Mol Cancer Res.
1:485–499. 2003.PubMed/NCBI
|
|
8.
|
Kakiuchi S, Daigo Y, Ishikawa N, et al:
Prediction of sensitivity of advanced non-small cell lung cancers
to gefitinib (Iressa, ZD1839). Hum Mol Genet. 13:3029–3043. 2004.
View Article : Google Scholar
|
|
9.
|
Kikuchi T, Daigo Y, Ishikawa N, et al:
Expression profiles of metastatic brain tumor from lung
adenocarcinomas on cDNA microarray. Int J Oncol. 28:799–805.
2006.PubMed/NCBI
|
|
10.
|
Taniwaki M, Daigo Y, Ishikawa N, et al:
Gene expression profiles of small-cell lung cancers: molecular
signatures of lung cancer. Int J Oncol. 29:567–575. 2006.PubMed/NCBI
|
|
11.
|
Bella J, Hindle KL, McEwan PA and Lovell
SC: The leucine-rich repeat structure. Cell Mol Life Sci.
65:2307–2333. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Chai L, Dai L, Che Y, et al: LRRC19, a
novel member of the leucine-rich repeat protein family, activates
NF-κB and induces expression of proinflammatory cytokines. Biochem
Biophys Res Commun. 388:543–548. 2009.PubMed/NCBI
|
|
13.
|
Kajava AV: Structural diversity of
leucine-rich repeat proteins. J Mol Biol. 277:519–527. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Pancer Z and Cooper MD: The evolution of
adaptive immunity. Annu Rev Immunol. 24:497–518. 2006. View Article : Google Scholar
|
|
15.
|
Feng Q, Cao R, Xia L, Erdjument-Bromage H,
Tempst P and Zhang Y: Identification and functional
characterization of the p66/p68 components of the MeCP1 complex.
Mol Cell Biol. 22:536–546. 2002. View Article : Google Scholar
|
|
16.
|
Ciavarella S, Milano A, Dammacco F and
Silverstris F: Targeted therapies in cancer. BioDrugs. 24:77–88.
2010. View Article : Google Scholar
|
|
17.
|
Suzuki C, Daigo Y, Ishikawa N, et al: ANLN
plays a critical role in human lung carcinogenesis through the
activation of RHOA and by involvement in the phosphoinositide
3-kinase/AKT pathway. Cancer Res. 65:11314–11325. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Ishikawa N, Daigo Y, Takano A, et al:
Characterization of SEZ6L2 cell-surface protein as a novel
prognostic marker for lung cancer. Cancer Sci. 97:737–745. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Kato T, Sato N, Takano A, et al:
Activation of placenta-specific transcription factor distal-less
homeobox 5 predicts clinical outcome in primary lung cancer
patients. Clin Cancer Res. 14:2363–2370. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Dunleavy EM, Roche D, Tagami H, et al:
HJURP is a cell-cycle-dependent maintenance and deposition factor
of CENP-A at centromeres. Cell. 137:485–497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Hirata D, Yamabuki T, Miki D, et al:
Involvement of epithelial cell transforming sequence-2 oncoantigen
in lung and esophageal cancer progression. Clin Cancer Res.
15:256–266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Sato N, Koinuma J, Fujita M, et al:
Activation of WD repeat and high-mobility group box DNA binding
protein 1 in pulmonary and esophageal carcinogenesis. Clin Cancer
Res. 16:226–239. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Sato N, Koinuma J, Ito T, et al:
Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7)
protein in pulmonary carcinogenesis. Genes Chromosomes Cancer.
49:353–367. 2010.PubMed/NCBI
|
|
24.
|
Nguyen MH, Koinuma J, Ueda K, et al:
Phosphorylation and activation of cell division cycle associated 5
by mitogen-activated protein kinase play a crucial role in human
lung carcinogenesis. Cancer Res. 70:5337–5347. 2010. View Article : Google Scholar
|
|
25.
|
Takano A, Ishikawa N, Nishino R, et al:
Identification of nectin-4 oncoprotein as a diagnostic and
therapeutic target for lung cancer. Cancer Res. 69:6694–6703. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Sato N, Yamabuki T, Takano A, et al: Wnt
inhibitor Dickkopf-1 as a target for passive cancer immunotherapy.
Cancer Res. 70:5326–5336. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Mizukami Y, Kono K, Daigo Y, et al:
Detection of novel cancer-testis antigen-specific T-cell responses
in TIL, regional lymph nodes, and PBL in patients with esophageal
squamous cell carcinoma. Cancer Sci. 99:1448–1454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Harao M, Hirata S, Irie A, et al:
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated
cancer testis antigen, cell division cycle associated 1, can induce
tumor-reactive CTL. Int J Cancer. 123:2616–2625. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Kono K, Mizukami Y, Daigo Y, et al:
Vaccination with multiple peptides derived from novel cancer-testis
antigens can induce specific T-cell responses and clinical
responses in advanced esophageal cancer. Cancer Sci. 100:1502–1509.
2009. View Article : Google Scholar
|
|
30.
|
Yokomine K, Senju S, Nakatsura T, et al:
The forkhead Box M1 transcription factor as a candidate of target
for anti-cancer immunotherapy. Int J Cancer. 126:2153–2163.
2010.PubMed/NCBI
|
|
31.
|
Tomita Y, Imai K, Senju S, et al: A novel
tumor-associated antigen, cell division cycle 45-like can induce
cytotoxic T-lymphocytes reactive to tumor cells. Cancer Sci.
102:697–705. 2011. View Article : Google Scholar
|
|
32.
|
Aragaki M, Takahashi K, Akiyama H, et al:
Characterization of a cleavage stimulation factor, 3′ pre-RNA,
subunit 2, 64 kDa (CSTF2) as a therapeutic target for lung cancer.
Clin Cancer Res. 17:5889–5900. 2011.
|
|
33.
|
Nishino R, Takano A, Oshita H, et al:
Identification of Epstein-Barr virus-induced gene 3 as a novel
serum and tissue biomarker and a therapeutic target for lung
cancer. Clin Cancer Res. 17:6272–6286. 2011. View Article : Google Scholar
|
|
34.
|
Masuda K, Takano A, Oshita H, et al:
Chondrolectin is a novel diagnostic biomarker and a therapeutic
target for lung cancer. Clin Cancer Res. 17:7712–7722. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Fujitomo T, Daigo Y, Matsuda K, Ueda K and
Nakamura Y: Critical function for nuclear envelope protein TMEM209
in human pulmonary carcinogenesis. Cancer Res. 72:4110–4118. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Koinuma J, Akiyama H, Fujita M, et al:
Characterization of an Opa interacting protein 5 involved in lung
and esophageal carcinogenesis. Cancer Sci. 103:577–586. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Nguyen MH, Ueda K, Nakamura Y and Daigo Y:
Identification of a novel oncogene, MMS22L, involved in lung
and esophageal carcinogenesis. Int J Oncol. 41:1285–1296. 2012.
|
|
38.
|
Oshita H, Nishino R, Takano A, et al:
RASEF is a novel diagnostic biomarker and a therapeutic target for
lung cancer. Mol Cancer Res. 11:937–951. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Tong ZB, Nelson LM and Dean J: Mater
encodes a maternal protein in mice with a leucine-rich repeat
domain homologous to porcine ribonuclease inhibitor. Mamm Genome.
11:281–287. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Mutai H, Toyoshima Y, Sun W, Hattori N,
Tanaka S and Shiota K: PAL31, a novel nuclear protein, expressed in
the developing brain. Biochem Biophys Res Commun. 274:427–433.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Bilder D and Perrimon N: Localization of
apical epithelial determinants by the basolateral PDZ protein
Scribble. Nature. 403:676–680. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Linhoff MW, Harton JA, Cressman DE, Martin
BK and Ting JP: Two distinct domains within CIITA mediate
self-association: involvement of the GTP-binding and leucine-rich
repeat domains. Mol Cell Biol. 21:3001–3011. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Inohara N, Koseki T, del Peso L, et al:
Nod1, an Apaf-1-like activator of caspase-9 and nuclear
factor-kappaB. J Biol Chem. 274:14560–14567. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Wu H, Maciejewski MW, Marintchev A,
Benashski SE, Mullen GP and King SM: Solution structure of a dynein
motor domain associated light chain. Nat Struct Biol. 7:575–579.
2000. View Article : Google Scholar
|
|
45.
|
Xu P, Mitchelhill KI, Kobe B, Kemp BE and
Zot HG: The myosin-I-binding protein Acan125 binds the SH3 domain
and belongs to the superfamily of leucine-rich repeat proteins.
Proc Natl Acad Sci USA. 94:3685–3690. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Brackertz M, Boeke J, Zhang R and
Renkawitz R: Two highly related p66 proteins comprise a new family
of potent transcriptional repressors interacting with MBD2 and
MBD3. J Biol Chem. 277:40958–40966. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Noh EJ, Lim DS and Lee JS: A novel role
for methyl CpG-binding domain protein 3, a component of the histone
deacetylase complex, in regulation of cell cycle progression and
cell death. Biochem Biophys Res Commun. 378:332–337. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Abbas T and Dutta A: p21 in cancer:
intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Wu S, Cetinkaya C, Munoz-Alonso MJ, et al:
Myc represses differentiation-induced p21CIP1 expression via
Miz-1-dependent interaction with the p21 core promoter. Oncogene.
22:351–360. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Reese KJ, Lin S, Verona RI, Schultz RM and
Bartolomei MS: Maintenance of paternal methylation and repression
of the imprinted H19 gene requires MBD3. PLoS Genet. 3:e1372007.
View Article : Google Scholar : PubMed/NCBI
|
